Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Luye Pharma Group's Total Liabilities for the quarter that ended in Dec. 2025 was HK$15,981 Mil.
Luye Pharma Group's quarterly Total Liabilities
increased
from Dec. 2024 (HK$14,796.37 Mil) to Jun. 2025 (HK$16,930.23 Mil) but then
declined
from Jun. 2025 (HK$16,930.23 Mil) to Dec. 2025 (HK$15,981.27 Mil).
Luye Pharma Group's annual Total Liabilities
increased
from Dec. 2023 (HK$13,084.03 Mil) to Dec. 2024 (HK$14,796.37 Mil) and
increased
from Dec. 2024 (HK$14,796.37 Mil) to Dec. 2025 (HK$15,981.27 Mil).
Luye Pharma Group Total Liabilities Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Luye Pharma Group's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of HK$15,981 Mil mean?
Luye Pharma Group (HKSE:02186) has a Total Liabilities of HK$15,981 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Luye Pharma Group and its competitors.
Is Luye Pharma Group's Total Liabilities too high?
Luye Pharma Group's current Total Liabilities is HK$15,981 Mil. Overall, Luye Pharma Group has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Total Liabilities compare to ZTS?
Luye Pharma Group's Total Liabilities of HK$15,981 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Luye Pharma Group and its competitors. Luye Pharma Group's current Total Liabilities is HK$15,981 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (HKSE:02186) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.19, compared to a current price of HK$2.12 — trading 33.7% below its estimated fair value. The current Total Liabilities is HK$15,981 Mil. Luye Pharma Group's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Luye Pharma Group (HKSE:02186), the current Total Liabilities is HK$15,981 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (HKSE:02186) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of HK$2.12 is trading 33.7% below its estimated GF Value™ of HK$3.19.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for HKSE:02186:
Total Liabilities: HK$15,981 Mil
GF Value™: HK$3.19 vs. price of HK$2.12 (33.7% below fair value)
No single metric tells the full story. See the HKSE:02186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
77GF Score
Get the complete analysis for HKSE:02186
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02186 has been successfully added to your 
